EP1191945A4 - Procedes et compositions pour la regulation de l'osteoformation par modulation de l'activite de la leptine - Google Patents

Procedes et compositions pour la regulation de l'osteoformation par modulation de l'activite de la leptine

Info

Publication number
EP1191945A4
EP1191945A4 EP00941311A EP00941311A EP1191945A4 EP 1191945 A4 EP1191945 A4 EP 1191945A4 EP 00941311 A EP00941311 A EP 00941311A EP 00941311 A EP00941311 A EP 00941311A EP 1191945 A4 EP1191945 A4 EP 1191945A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
control
bone formation
formation via
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00941311A
Other languages
German (de)
English (en)
Other versions
EP1191945A1 (fr
Inventor
Gerard Karsenty
Patricia Ducy
Michael Amling
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of EP1191945A1 publication Critical patent/EP1191945A1/fr
Publication of EP1191945A4 publication Critical patent/EP1191945A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP00941311A 1999-06-11 2000-06-09 Procedes et compositions pour la regulation de l'osteoformation par modulation de l'activite de la leptine Withdrawn EP1191945A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US489973 1995-06-13
US13873399P 1999-06-11 1999-06-11
US138733P 1999-06-11
US160441P 1999-10-10
US16044199P 1999-10-19 1999-10-19
US48987300A 2000-01-20 2000-01-20
PCT/US2000/015911 WO2000076552A1 (fr) 1999-06-11 2000-06-09 Procedes et compositions pour la regulation de l'osteoformation par modulation de l'activite de la leptine

Publications (2)

Publication Number Publication Date
EP1191945A1 EP1191945A1 (fr) 2002-04-03
EP1191945A4 true EP1191945A4 (fr) 2003-04-23

Family

ID=27385218

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00941311A Withdrawn EP1191945A4 (fr) 1999-06-11 2000-06-09 Procedes et compositions pour la regulation de l'osteoformation par modulation de l'activite de la leptine

Country Status (4)

Country Link
EP (1) EP1191945A4 (fr)
JP (1) JP2003528804A (fr)
CA (1) CA2376933A1 (fr)
WO (1) WO2000076552A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169559B2 (en) * 2002-05-13 2007-01-30 Fonterra Corporate Research and Development Ltd. LDL receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
DE10353593A1 (de) * 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
JP2006094720A (ja) * 2004-09-28 2006-04-13 Nakamura Sangyo Gakuen 骨系細胞培養用基質および骨系細胞の培養方法
JP5622720B2 (ja) 2008-05-21 2014-11-12 ニューロテスインコーポレイテッド 神経原繊維変化に関連する進行性認知障害の治療方法
CA2742600A1 (fr) 2008-11-04 2010-05-14 Nikolaos Tezapsidis Compositions a base de leptine et methodes de traitement de troubles evolutifs de la fonction cognitive provoques par une accumulation d'enchevetrements neurofibrillaires et de beta-amyloide

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698389A (en) * 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
US7063958B1 (en) * 1996-01-16 2006-06-20 The Rockefeller University Nucleic acids db, the receptor for leptin
EP0917469A1 (fr) * 1996-04-19 1999-05-26 ZymoGenetics, Inc. Procedes permettant d'induire la formation osseuse
EP0950417A3 (fr) * 1998-02-23 2000-02-23 Pfizer Products Inc. Traitement d' anomalies du squelette
WO1999053939A1 (fr) * 1998-04-20 1999-10-28 Mayo Foundation For Medical Education And Research Traitement de l'osteoporose par la leptine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUCY PATRICIA ET AL: "Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass.", CELL, vol. 100, no. 2, 21 January 2000 (2000-01-21), pages 197 - 207, XP002231771, ISSN: 0092-8674 *
See also references of WO0076552A1 *

Also Published As

Publication number Publication date
EP1191945A1 (fr) 2002-04-03
JP2003528804A (ja) 2003-09-30
WO2000076552A1 (fr) 2000-12-21
WO2000076552A8 (fr) 2001-07-05
CA2376933A1 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
AU6936800A (en) Method of treating bone for implantation and resulting bone
AU2777399A (en) Bone prosthesis and method of implantation
AU1515901A (en) Implant consisting of bone material
AU2001293178A1 (en) Dental implant system and additional methods of attachment
EP1059067B8 (fr) Traitement par ablation des métastases osseuses
AU3387599A (en) Methods and compositions for tissue regeneration
AU2622900A (en) Bone cement mixer and method
GB9808052D0 (en) Implants for administering substances and methods of producing implants
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU2111500A (en) Bone tissue regenerating composition
EP1089723A4 (fr) Methodes therapeutiques utilisant des derives de bisulfure de dithiocarbamates et compositions utilisees
HUP0201598A3 (en) Pharmaceutical composition comprising erythropoietin for modulation of excitable tissue function and their use
AU3475099A (en) Composition for tissue welding and method of use
AU3998400A (en) Methods of treating c1s-mediated diseases and conditions, and compounds and compositions therefor
AU7748000A (en) Method and composition for the treatment of dermatologic diseases
EP1109548A4 (fr) Utilisation de procedes et de compositions a base de tocotrienols pour traiter et prevenir les maladies osseuses
AU6686400A (en) Emg control of prosthesis
AU1854401A (en) Bone implant
AP2001002171A0 (en) Compositions and methods for controlling insects
AU2668699A (en) Methods and compositions for modulating leptin activity
HK1049618A1 (zh) 骨質形成調節
WO2001091700A8 (fr) Composition et procede destine a ameliorer l'elasticite des tissus
AU2002246849A1 (en) Agents and methods for promoting bone growth
EP1191945A4 (fr) Procedes et compositions pour la regulation de l'osteoformation par modulation de l'activite de la leptine
EP1542719A4 (fr) Procedes et compositions de regulation de formation d'os par modulation du tonus sympathique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030311

17Q First examination report despatched

Effective date: 20030716

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050531